comparemela.com
Home
Live Updates
Iptacopan Demonstrates 38.3% Proteinuria Reduction in Patients With IgAN : comparemela.com
Iptacopan Demonstrates 38.3% Proteinuria Reduction in Patients With IgAN
Iptocopan demonstrated superiority when treating patients with immunoglobulin A nephropathy and is the first drug to specifically target the alternative complement pathway.
Related Keywords
Argentina ,
Buenos Aires ,
Distrito Federal ,
David Soergel ,
Dana Rizk ,
Novartis Pharmaceuticals ,
University Of Alabama At Birmingham ,
World Congress ,
Metabolism Development Unit ,
Novartis ,
Primary Iga Nephropathy Patients ,
Functional Assessment ,
Chronic Illness Therapy Fatigue ,
comparemela.com © 2020. All Rights Reserved.